Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q2 2014 · 10-Q
Revenue—
Net Income-$3.25M-$3.25MN/M vs Q2 2013 EPS Diluted-$0.07-$0.07N/M vs Q2 2013 Operating Income-$3,257,000N/M Operating Cash Flowderived-$2,591,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,591,000— ended Jun 30, 2014 · filed Aug 6, 2014 · 37 d after period end